Company Filing History:
Years Active: 2011-2012
Title: The Innovator Behind Tumour Cell Lines: Marion Schlangstedt
Introduction
Marion Schlangstedt, an accomplished inventor based in Berlin, Germany, has made significant contributions to the field of biotechnology. With a focus on the development of tumour cell lines, her innovative work addresses crucial aspects of cancer treatment and prevention. With a total of two patents to her name, Marion's contributions are paving the way for advancements in therapeutic formulations.
Latest Patents
Marion Schlangstedt’s latest patents revolve around the invention of tumour cell lines, specifically detailing two cell lines designated as NM-F9 and NM-D4, with respective DSMZ accession numbers DSM ACC2606 and DSM ACC2605. The invention encompasses not only the cell lines themselves but also the lysates derived from these cell lines, which can be utilized in various compositions, including pharmaceutical and vaccine formulations. Moreover, Marion's patent provides methods for creating these compositions aimed at enhancing vaccination efficacy against cancers and tumourous diseases, highlighting her dedication to fighting against these critical health challenges.
Career Highlights
Marion works with Glycotope GmbH, a company known for its cutting-edge research in glycoscience and biopharmaceutical development. Her role at Glycotope exemplifies her commitment to pushing the boundaries of scientific discovery in the biotech field. Over the years, Marion has consistently demonstrated her innovative spirit and expertise in cancer research, contributing valuable inventions that not only advance medical science but also hold the potential for real-world applications in patient care.
Collaborations
Throughout her career, Marion Schlangstedt has collaborated with talented professionals, including coworkers Steffen Goletz and Hans Baumeister. These collaborations reflect her ability to work effectively within a team environment, enhancing the creative process and leading to the development of innovative solutions in biomedicine. Together, they strive to create impactful advancements that can improve health outcomes for individuals facing cancer.
Conclusion
As a prominent inventor in the realm of cancer research and biotechnology, Marion Schlangstedt's contributions have significant implications for future therapies and vaccine development. Her work on tumour cell lines and associated methods is a testament to her innovation-driven approach, which continues to inspire advancements in science and medicine. Through her patents and collaborations, Marion exemplifies the critical role that inventors play in shaping the future of healthcare.